CARA THERAPEUTICS INC (CARA) Stock Price, Forecast & Analysis
USA - NASDAQ:CARA - US1407552082 - Common Stock
CARA Key Statistics, Chart & Performance
The current stock price of CARA is 5.32 USD. In the past month the price increased by 2.31%. In the past year, price decreased by -32.93%.
CARA Latest News, Press Relases and Analysis
CARA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.55 | 3.94B |
Related stock screener links
About CARA
Company Profile
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 10 full-time employees. The company went IPO on 2014-01-31. The firm is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. The company is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. The company is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. The company has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Company Info
CARA THERAPEUTICS INC
400 Atlantic Street, Suite 500
Stamford CONNECTICUT 06902 US
CEO: Derek Chalmers
Employees: 55
Phone: 12034063700
CARA THERAPEUTICS INC / CARA FAQ
What does CARA do?
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 10 full-time employees. The company went IPO on 2014-01-31. The firm is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. The company is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. The company is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. The company has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
What is the stock price of CARA THERAPEUTICS INC today?
The current stock price of CARA is 5.32 USD. The price decreased by -4.14% in the last trading session.
Does CARA stock pay dividends?
CARA does not pay a dividend.
How is the ChartMill rating for CARA THERAPEUTICS INC?
CARA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does CARA THERAPEUTICS INC have?
CARA THERAPEUTICS INC (CARA) currently has 55 employees.
Can you provide the market cap for CARA THERAPEUTICS INC?
CARA THERAPEUTICS INC (CARA) has a market capitalization of 24.31M USD. This makes CARA a Nano Cap stock.
CARA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CARA. When comparing the yearly performance of all stocks, CARA is a bad performer in the overall market: 65.9% of all stocks are doing better.
CARA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CARA. The financial health of CARA is average, but there are quite some concerns on its profitability.
CARA Financial Highlights
Over the last trailing twelve months CARA reported a non-GAAP Earnings per Share(EPS) of -15.55. The EPS decreased by -612.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -161.7% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CARA Forecast & Estimates
For the next year, analysts expect an EPS growth of 40% and a revenue growth -25% for CARA